• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study backs next-gen Medtronic MiniMed 780G insulin pump

September 1, 2022 By Sean Whooley

Medtronic MiniMed 780G
The Medtronic MiniMed 780G system. [Image from Medtronic]
Medtronic (NYSE:MDT) today announced positive results from a study of its next-generation MiniMed 780G automated insulin delivery system.

Results from the ADAPT study, published in The Lancet Diabetes & Endocrinology, demonstrated improved glycemic control and treatment satisfaction among users of MiniMed 780G.

The MiniMed 780G system is available in more than 60 countries. It is currently under FDA review. Medtronic is hopeful for clearance during the current fiscal year. If clearance takes place, it would be good news for a Diabetes business that has faced regulatory troubles. (The company recently said that it’s achieved 90% of the FDA’s action items.)

More about the ADAPT study

The study enrolled 82 individuals with type 1 diabetes not currently meeting glycemic targets. It evaluated MiniMed 780G against the standard of care (multiple daily injections plus continuous glucose monitoring). On average, enrollees scanned CGM frequently (~9 scans/day) but had suboptimal HbA1C above 8% at baseline.

Medtronic’s study randomized half of the participants to stay on standard of care, with the rest directly transitioned to MiniMed 780G. Results demonstrated improvements in glycemic targets for those on MiniMed 780G with a significant and sustained 1.4% HbA1C reduction at six months.

Users of MiniMed 780G also saw a 27.6% increase in time in range. That amounted to 6.6 more hours per day in target range compared to standard of care. Users also saw no increase in time in hypoglycemia. The improvement proved even greater overnight with the algorithm in full control.

“The ADAPT study illustrates that insulin pump therapy with advanced algorithms, like that of the MiniMed 780G system, can produce significantly improved clinical results versus the current standard of care,” said Dr. Ohad Cohen, senior global medical affairs director, Medtronic Diabetes. “Studies like this can change how health care systems define standard of care and expand options for people living with diabetes to begin using insulin pumps sooner to improve their glycemic control and help reduce the burden of diabetes.”

At six months, 27.8% of MiniMed 780G users achieved HbA1c below 7% at six months. No individuals remaining on MDI and CGM achieved that result.

Users of MiniMed 780G spent 95.8% of their time in SmartGuard advanced hybrid closed-loop delivery mode. They experienced few system exits (0.9 per week). They used the sensor 92.2% of the time compared to 87.3% in the standard of care group. The study demonstrated a significant increase in treatment satisfaction and a reduction in fear of hypoglycemia.

Medtronic said the use of MiniMed 780G — even when paired with the Guardian 3 sensor that requires two fingerstick calibrations per day — significantly improved all glycemic metrics compared to the standard of care. The company concluded that it supports use at early stages in the treatment pathway.

Filed Under: Auto-injectors, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS